Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;30(2):135-143.
doi: 10.3350/cmh.2023.0412. Epub 2024 Jan 5.

Comprehensive approach to controlling chronic hepatitis B in China

Shan Shan  1 , Xinyan Zhao  1 , Jidong Jia  1
Affiliations
Review

Comprehensive approach to controlling chronic hepatitis B in China

Shan Shan et al. Clin Mol Hepatol. 2024 Apr.

Abstract

Hepatitis B virus (HBV) infection was highly endemic in China, where the prevalence of HBsAg was 9.7% in 1992. Comprehensive strategies, including universal infant hepatitis B vaccination with emphasis on timely birth-dose and 3-dose coverage, dramatically reduced the mother-to-infant transmission and early childhood acquisition of HBV, resulting in estimated HBsAg prevalence rates of 5.6% and 0.1% in the general population and among children aged <5 years in 2022, respectively. Clinical guidelines on the prevention and treatment of chronic hepatitis B have been periodically updated based on emerging evidence from clinical research. The continuously improved reimbursement policy and the massively reduced price of antiviral drugs through government negotiation and central procurement have increased treatment accessibility and affordability. However, due to the low rates of diagnosis and treatment, China still faces a large challenge in achieving the 2030 goal of lowering HBV-related mortality by 65%. A public health approach involving concerted efforts from the government, medical community, industry, and society as a whole would be necessary to increase the uptake of HBV tests and treatment to achieve the global goal of eliminating viral hepatitis as a public health threat by 2030.

Keywords: China; Health insurance reimbursement; Hepatitis B; Prevention; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts to disclose.

Figures

Figure 1.
Figure 1.
Milestones for the prevention of HBV infection in China. HBV, hepatitis B virus; HIV, human immunodeficiency virus; MTCT, motherto-child transmission.
Figure 2.
Figure 2.
Increasing HepB coverage and decreasing HBsAg prevalence in China. HepB, hepatitis B vaccination; HBsAg, hepatitis B surface antigen.
Figure 3.
Figure 3.
Milestones for the treatment of CHB in China. CHB, chronic hepatitis B; NCDP, National Centralized Drug Procurement; HBV, hepatitis B virus.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22:19–32. - PubMed
    1. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14:381–396. - PubMed
    1. World Health Organization (WHO) Global progress report on HIV, viral hepatitis and sexually transmitted infections. 2021. WHO web site, < https://www.who.int/publications/i/item/9789240027077>. Accessed 31 Aug 2023.
    1. Chen S, Li J, Wang D, Fung H, Wong LY, Zhao L. The hepatitis B epidemic in China should receive more attention. Lancet. 2018;391:1572. - PubMed
    1. Polaris Observatory Collaborators Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403. - PubMed

Substances